Adaptive Biotechnologies (ADPT): Equity Research Initiation (2023-2025)
Investment Summary
- Adaptive Biotechnologies has executed a significant turnaround over the last three years. The company transitioned from revenue contraction and heavy losses in FY2023 to robust double-digit growth, positive adjusted EBITDA, and sharply narrowed net losses by FY2025.
- The MRD (Minimal Residual Disease) diagnostics business is the primary growth engine, with clonoSEQ test volumes and revenue expanding rapidly due to increased clinical adoption, payer coverage, and higher ASPs. MRD segment profitability was achieved in mid-2025.
- The Immune Medicine segment has been volatile, with revenue swings tied to the Genentech collaboration and recent strategic refocus toward monetizing proprietary TCR-antigen data and new pharma partnerships (notably Pfizer).
- Operating leverage and cost discipline have improved, with operating expenses flat YoY in FY2025 despite strong revenue growth, and cash burn reduced substantially.
- Key risks include the loss of the Genentech collaboration, competitive threats in MRD testing, and the need to replace one-off Immune Medicine revenue streams.
- The company is well-capitalized, ending FY2025 with $227.2M in cash and equivalents (excluding Digital Biotechnologies), and in June 2026 issued $345M of 0% convertible notes due 2031, using part of the proceeds to retire the OrbiMed revenue interest agreement.
Business Overview
Adaptive Biotechnologies operates two main businesses:
- MRD (Minimal Residual Disease): Clinical diagnostics for hematologic malignancies, primarily via the FDA-authorized clonoSEQ assay. Revenue is driven by clinical test volume, ASP expansion, and pharma collaborations/milestones.
- Immune Medicine: Immune receptor sequencing, data licensing, TCR-antigen prediction models, and target discovery for pharma partners. Recent focus is on monetizing large proprietary datasets and AI/ML applications.
Financial Snapshot: Fiscal Years
Key Material Information (FY2023-FY2025)
| Metric | FY2025 (2025-12-31) | FY2024 (2024-12-31) | FY2023 (2023-12-31) |
|---|---|---|---|
| Revenue ($M) | 277.0 | 179.0 | 170.3 |
| YoY Revenue Growth | +55% | +5% | -8% |
| Net Loss ($M) | -59.5 | -159.5 | -225.3 |
| Adjusted EBITDA ($M) | 12.2 | -80.4 | -116.4 |
| Cash, Equiv. & Marketable Sec. ($M)* | 227.2 | 256.0 | 346.4 |
| clonoSEQ Test Volume | 105,587 | 76,105 | 56,496 |
| MRD Revenue ($M) | 212.3 | 145.5 | 102.7 |
| IM Revenue ($M) | 64.6 | 33.4 | 67.5 |
| R&D Expense ($M) | 93.8 | 103.0 | 122.1 |
| Sales & Marketing Expense ($M) | 94.6 | 84.8 | 88.6 |
| General & Admin Expense ($M) | 72.7 | 72.8 | 83.9 |
| Operating Cash Flow ($M) | -46.0 | -95.2 | -156.3 |
*Excludes $13.1M at Digital Biotechnologies, Inc. as of FY2025.
Segment Analysis: Fiscal Years
MRD Segment
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue ($M) | 212.3 | 145.5 | 102.7 |
| YoY Growth (%) | +46 | +42 | - |
| clonoSEQ Test Volume | 105,587 | 76,105 | 56,496 |
| Volume Growth (%) | +39 | +35 | +53 |
| Coverage (lives, MM/ALL) | >300M | >300M | 300M |
| Pharma Backlog ($M) | 245 (Q2'26) | 218 (Q2'25) | - |
Immune Medicine Segment
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue ($M) | 64.6 | 33.4 | 67.5 |
| YoY Growth (%) | +93 | -51 | - |
| Key Partnerships | Pfizer | Genentech | Genentech |
Quarterly Financial Snapshot (Most Recent Quarters)
| Quarter | Total Revenue ($M) | MRD Revenue ($M) | MRD Clinical Volume | U.S. ASP ($/test) | Sequencing Gross Margin (%) | Adjusted EBITDA ($M) | Cash & Equivalents ($M) |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 71.6 | 66.2 | 36,100 | 1,382 | 72 | 9.1 | 357 |
| Q1 2026 | 70.9 | 67.1 | 32,600 | 1,360 | 70 | 12.1 | 222 |
| Q4 2025 | 71.7 | 61.9 | 30,038 | 1,350 | 71 | 15.2 | 227 |
| Q3 2025 | 94.0 | 56.8 | 27,111 | 1,340 | 66 | 7.0 | 217 |
Key Bullish and Bearish Points
| Bullish Points | Bearish Points |
|---|---|
| Strong MRD revenue and test volume growth (+46% YoY in FY2025; +39% volume) | Still unprofitable on GAAP basis; net loss of -$59.5M in FY2025 |
| Positive Adjusted EBITDA in FY2025 ($12.2M); MRD segment profitable since Q2'25 | Immune Medicine segment revenue highly dependent on one-off events |
| Expanding clinical adoption and payor coverage for clonoSEQ | Termination of Genentech collaboration removes major future revenue stream |
| Large cash balance ($227.2M) and reduced cash burn | High R&D and S&M expenses relative to revenue |
| Strategic partnerships (Pfizer, NeoGenomics) | Competitive landscape in MRD and immune medicine is intensifying |
| Operating expenses flat YoY in FY2025 despite revenue growth | $345M convertible notes due 2031 add leverage |
| Sequencing gross margin expansion (72% in Q2 2026, +9pp YoY) | Lumpy pharma milestone revenue; not recurring every quarter |
Positive and Negative Catalysts
| Positive Catalysts | Negative Catalysts |
|---|---|
| Further expansion of clonoSEQ reimbursement and clinical penetration | Loss of additional key partnerships or collaborations |
| Regulatory approvals for new indications (e.g., NHL subtypes, international) | Failure to achieve further clinical adoption or reimbursement gains |
| Additional pharma/biotech partnerships in IM segment | Increased competition in MRD testing (new entrants, alternative tech) |
| Monetization of large TCR-antigen datasets (AI/ML applications) | Adverse regulatory changes (e.g., LDT regulation tightening) |
| Progress toward profitability and sustained positive EBITDA | Delays or failures in expanding into new markets or indications |
| Expansion of Medicare bundle, payer contract renegotiations | Lumpy pharma revenue; milestone payments not guaranteed |
| Completion of Immune Medicine separation unlocking shareholder value | Execution risk in Immune Medicine separation process |
Top Questions to Ask Before Investing
- Sustainability of MRD Growth: Can Adaptive maintain high double-digit growth in MRD revenue and clonoSEQ test volume as penetration increases?
- Path to GAAP Profitability: What are the key levers and timeline for achieving sustained GAAP profitability?
- Immune Medicine Revenue Mix: How will the company replace the lost Genentech collaboration revenue, and what is the pipeline for new IM partnerships?
- Competitive Positioning: How defensible is Adaptive’s technology and market share against emerging competitors and alternative MRD testing modalities?
- Regulatory Risk: What is the potential impact of evolving FDA regulation on LDTs and NGS-based diagnostics?
- Capital Allocation: How will Adaptive deploy its substantial cash reserves, and is further dilution or debt likely?
- Convertible Notes: How will the $345M of 0% convertible notes due 2031 affect dilution and financial flexibility?
- International Expansion: What is the strategy and timeline for meaningful revenue outside the U.S.?
- Pharma Milestone Visibility: How lumpy is pharma revenue, and what is the visibility on future milestone payments?
- Execution on Partnerships: What are the key execution risks in EMR integration, community adoption, and new partnerships (e.g., NeoGenomics)?
